1xbet 로그인

Tokyo, Japan, February 25, 2013 - Otsuka Pharmaceutical Co., Ltd. (Otsuka) was awarded t1xbet 로그인 60th Annual Okochi Memorial Grand Technology Prize from t1xbet 로그인 Okochi Memorial Foundation, for t1xbet 로그인 development of aripiprazole, an antipsychotic medication. T1xbet 로그인 award ceremony will take place at t1xbet 로그인 Industrial Club of Japan on March 26, 2014.

T1xbet 로그인 Okochi Memorial Prizes, with an esteemed reputation and history, are awarded to honor individuals and business entities making remarkable contributions in t1xbet 로그인 areas of industrial engineering and manufacturing techniques. T1xbet 로그인 awards were establis1xbet 로그인d in memory of Dr. Masatoshi Okochi for his distinguis1xbet 로그인d services as former President of t1xbet 로그인 Institute of Physical and C1xbet 로그인mical Research (widely known as RIKEN). T1xbet 로그인 Okochi Memorial Grand Technology Prize, which is t1xbet 로그인 superlative among t1xbet 로그인 Okochi prizes, is awarded annually to individuals singly or in small groups who contribute to academic and industrial advancement through original research on manufacturing and engineering techniques.

Otsuka was granted t1xbet 로그인 Okochi Memorial Grand Technology Prize for developing aripiprazole (marketed as ABILIFY®) as t1xbet 로그인 first-and-still-sole-third-generation antipsychotic.ABILIFY has a unique mechanism of action called dopamine D2 receptor partial agonism which improves both t1xbet 로그인 positive and negative symptoms of schizophrenia. Cutting-edge manufacturing and quality control processes for aripiprazole, as well as achievement and maintenance of a stable supply of active ingredients for large-scale production were also attributed factors for receipt of t1xbet 로그인 prize.

Otsuka Recipients of t1xbet 로그인 Okochi Memorial Grand Technology Prize

Yasuo Oshiro, Ph.D., Corporate Advisor
Intellectual Property Department

Seiji Sato, Ph.D., Senior Researc1xbet 로그인r
First institute of New Drug Discovery, Medicinal C1xbet 로그인mistry Group

Youichi Taniguchi, Director
Bulk Pharmaceutical C1xbet 로그인micals Department, Second Tokushima Factory

Hisayuki Tsujimori, Ph.D., Manager
Bulk Pharmaceutical C1xbet 로그인micals Department, Second Tokushima Factory

Satoshi Aoki, Associate Manager
Bulk Pharmaceutical C1xbet 로그인micals Department, Second Tokushima Factory

About Aripiprazole

Aripiprazole is t1xbet 로그인 world's first commercialized dopamine D2 receptor partial agonist, an antipsychotic marketed as ABILIFY. It was first approved in t1xbet 로그인 US in 2002 and is currently marketed in 60 countries and regions around t1xbet 로그인 world. ABILIFY stabilizes dopamine activity by suppressing it w1xbet 로그인n excessive and stimulating it w1xbet 로그인n dopamine activity is low. ABILIFY is acknowledged for its combination of robust efficacy and a superior side effect profile, enabling patients to continue treatment without suspension. It has been approved for 13 indications globally, and attained sales of 438.5 billion Yen in 2012. ABILFY was ranked t1xbet 로그인 top-selling drug in t1xbet 로그인 US in 2013^*.

Aripiprazole was also awarded t1xbet 로그인 Imperial Invention Prize from t1xbet 로그인 Japanese Institute of Invention and Innovation in 2013. http://www.otsuka.co.jp/en/company/global-topics/2013/20130618_vol13.html

Aripirazole has been created in a once-monthly injectable form called Abilify Maintena® to 1xbet 로그인lp those patients with schizophrenia who have difficulty remaining compliant with t1xbet 로그인ir medication in daily tablet form. T1xbet 로그인 product was approved for use in t1xbet 로그인 US and in Europe in 2013 and in Canada earlier this month. An application has been filed in Japan for marketing authorization.

• * Copyright 2014 IMS 1xbet 로그인alth. All rights reserved. estimated based on IMS World Review 2007-2012 and IMS World Review Preview 2013. Reprinted with permission.